Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2024-01-30 Earnings Release
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from JW Life Science regarding a change in sales or profit structure (exceeding 30%). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year compared to the previous year. This type of disclosure is a standard preliminary earnings announcement required by the Korea Exchange (KRX) for listed companies, which falls under the 'Earnings Release' category as it provides key financial highlights before the final audited report. FY 2023
2024-01-30 Korean
수시공시의무관련사항(공정공시)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Life Science regarding a planned cash dividend of 500 KRW per share for the 2023 fiscal year. It specifies the dividend amount and the record date (December 31, 2023). This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2023-12-15 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is titled '분기보고서' (Quarterly Report) for JW Life Science, covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-13 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Disclosure' (영업(잠정)실적) for JW Life Science. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the third quarter of 2023 compared to previous periods. This is a standard initial announcement of financial results, which fits the definition of an Earnings Release (ER). Q3 2023
2023-11-09 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for JW Life Science, covering the period from January 1, 2023, to June 30, 2023. It contains comprehensive financial data, including balance sheets, income statements, and detailed business operations, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for JW Life Science, detailing quarterly financial highlights such as revenue, operating profit, and net income. It is a short, structured announcement of financial results rather than a full report, fitting the definition of an Earnings Release (ER). H1 2023
2023-08-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.